original ) (raw )SAT0430 SECUKINUMAB EFFECTIVENESS IN 1543 PATIENTS WITH PSORIATIC ARTHRITIS TREATED IN ROUTINE CLINICAL PRACTICE IN 13 EUROPEAN COUNTRIES IN THE EuroSpA RESEARCH COLLABORATION NETWORK
Björn Guðbjörnsson
Annals of the Rheumatic Diseases, 2020
View PDFchevron_right
Real-world evidence for secukinumab in UK patients with psoriatic arthritis or radiographic axial spondyloarthritis: interim 2-year analysis from SERENA
Yusuf Patel
Rheumatology Advances in Practice
View PDFchevron_right
Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study
Mariagrazia Lorenzin
RMD Open
View PDFchevron_right
One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study
Rossana Scrivo
Expert Opinion on Biological Therapy
View PDFchevron_right
Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study
Rubén Queiro
Frontiers in Medicine
View PDFchevron_right
Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort
Roberta Ramonda
Research Square (Research Square), 2024
View PDFchevron_right
Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort
Vincenzo Parrino
Advances in Rheumatology
View PDFchevron_right
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5‐year Results from the Phase 3 FUTURE 1 Study
Juergen Rech
ACR Open Rheumatology
View PDFchevron_right
Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients
Ana-maria Orbai
The Journal of Rheumatology, 2019
View PDFchevron_right
Real‐World Six‐ and Twelve‐Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries
Björn Guðbjörnsson
Arthritis Care & Research, 2021
View PDFchevron_right
AB0761 SECUKINUMAB for the Treatment of Psoriatic Arthritis in Real Life: An Italian Experience
Roberta Ramonda
Abstracts accepted for Publication, 2019
View PDFchevron_right
Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study
Alan Kivitz
The Journal of rheumatology, 2016
View PDFchevron_right
Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study
Alan Kivitz
Rheumatology and Therapy, 2019
View PDFchevron_right
Secukinumab treatment in spondyloarthritis: Retention rate and effectiveness data at 12 months – data from the Romanian Registry of Rheumatic Diseases
Simona Rednic
Romanian Journal of Rheumatology, 2020
View PDFchevron_right
Secukinumab Efficacy on Psoriatic Arthritis GRAPPA-OMERACT Core Domains in Patients with or Without Prior Tumor Necrosis Factor Inhibitor Use: Pooled Analysis of Four Phase 3 Studies
Ana-maria Orbai
Rheumatology and Therapy
View PDFchevron_right
Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison
DAMIEN LOEUILLE
Rheumatology, 2020
View PDFchevron_right
Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study
Todd Fox
Arthritis Research & Therapy, 2018
View PDFchevron_right
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial
Kevin Ding
The Lancet, 2020
View PDFchevron_right
Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
Martin M Schumacher
Annals of the Rheumatic Diseases, 2013
View PDFchevron_right
Secukinumab real world drug retention compared to TNF-alpha inhibitors in psoriatic arthritis
Tali Eviatar
Clinical and Experimental Rheumatology, 2022
View PDFchevron_right
Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis
vibeke strand
Journal of Comparative Effectiveness Research
View PDFchevron_right
Evidence for the Use of Secukinumab in Patients with Radiographic and Non-radiographic Axial Spondyloarthritis in the Last 5 Years
Carlos A Guillen Astete
Rheumatology and therapy, 2021
View PDFchevron_right
Prompt Clinical Response to Secukinumab in Patients with Axial Spondyloarthritis: Real Life Observational Data from Three Italian Referral Centers
Giovanni Lapadula
The Israel Medical Association journal : IMAJ, 2018
View PDFchevron_right
Secukinumab demonstrates sustained efficacy in moderate to severe plaque psoriasis across disease severity subgroups
Summer Xia
Journal of the American Academy of Dermatology, 2015
View PDFchevron_right
Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)
Ricardo Blanco
Arthritis research & therapy, 2018
View PDFchevron_right
Treatment with Ixekizumab Following Secukinumab Failure in Patients with Psoriatic Arthritis: Real-Life Experience from a Resistant Population
Amir Haddad
Biologics : Targets & Therapy, 2021
View PDFchevron_right
Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison
vibeke strand
Rheumatology and therapy, 2017
View PDFchevron_right
Evaluation of the Feasibility of a Web-Based Survey to Assess Patient-Reported Symptom Improvement and Treatment Satisfaction Among Patients with Psoriatic Arthritis Receiving Secukinumab
Lori McLeod
Clinical Drug Investigation
View PDFchevron_right
Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)
Diamant Thaci
Journal of the European Academy of Dermatology and Venereology, 2018
View PDFchevron_right
15353 Presence of psoriatic arthritis has no impact on the clinical efficacy and safety of secukinumab in patients with psoriasis: Pooled analysis of four phase 3 clinical trials
Braulio Gomez
Journal of the American Academy of Dermatology, 2020
View PDFchevron_right